AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27464316 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) scores
Number of subjects: 235
Study 27464316 — intervention group
Group type: COMPARATOR
Intervention: Generalized Anxiety Disorder presence
Number of subjects: 235
Study 27464553 — intervention group
Group type: EXPERIMENTAL
Intervention: IR1 sign (temperature of cancer site minus that of the contralateral mirror imaging site)
Number of subjects: 143
Study 27464553 — intervention group
Group type: EXPERIMENTAL
Intervention: IR1 sign
Number of subjects: 143
Study 27464553 — intervention group
Group type: EXPERIMENTAL
Intervention: IR1 and IR5 (asymmetrical thermographic pattern)
Number of subjects: 143
Study 27464588 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Number of subjects: 2570
Study 27464588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2570
Study 27464708 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) with clipping for deep mural injury (DMI)
Number of subjects: 802
Study 27464708 — intervention group
Group type: EXPERIMENTAL
Intervention: Type III-V DMI
Number of subjects: 802
Study 27464708 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I/II DMI
Number of subjects: 802
Study 27464822 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC negative patients
Number of subjects: 200
Study 27464822 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC negative patients (G2 grading)
Number of subjects: 200
Study 27464822 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC negative patients with no lymph node metastasis
Number of subjects: 200
Study 27464822 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt1 and PlGF
Number of subjects: 200
Study 27464938 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated shRNA targeting GHSR1a
Number of subjects: 0
Study 27464938 — intervention group
Group type: COMPARATOR
Intervention: Blank control (BC)
Number of subjects: 0
Study 27464938 — intervention group
Group type: COMPARATOR
Intervention: Scrambled control (SC)
Number of subjects: 0
Study 27464938 — intervention group
Group type: EXPERIMENTAL
Intervention: GHSR1a knockdown in vivo
Number of subjects: 0
Study 27464938 — intervention group
Group type: COMPARATOR
Intervention: Blank control tumors
Number of subjects: 0
Study 27464938 — intervention group
Group type: COMPARATOR
Intervention: Negative control tumors
Number of subjects: 0
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioneuroma (GN)
Number of subjects: 217
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioneuroblastoma intermixed (GNBI)
Number of subjects: 217
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 217
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual tumors (42 GN, 13 GNBI)
Number of subjects: 217
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal resection
Number of subjects: 217
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganglioneuroma (GN) and Ganglioneuroblastoma intermixed (GNBI)
Number of subjects: 217
Study 27465021 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 217
Study 27465105 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 21
Study 27465382 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D concentrations
Number of subjects: 100
Study 27465398 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 59
Study 27465398 — intervention group
Group type: COMPARATOR
Intervention: Control (no MVPA)
Number of subjects: 59
Study 27465398 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall weight, BMI, fat mass, and subcutaneous adiposity
Number of subjects: 59
Study 27465647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (4 mg/kg) administered prior to MRI
Number of subjects: 20
Study 27466046 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled SMS text message reminder for MV
Number of subjects: 990
Study 27466046 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice call plus SMS text message reminder for MV
Number of subjects: 990
Study 27466046 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 990
Study 27466046 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Intervention and Control)
Number of subjects: 990
Study 27466061 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly-developed, higher-concentration formulation of a dual-acting antihistamine-mast cell stabilizer, once-daily dosing.
Number of subjects: 0
Study 27466061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-acting antihistamine-mast cell stabilizing agents (first-line therapeutics for AC).
Number of subjects: 0
Study 27466073 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant recommendation for a 12-year-old patient with high caries risk in three hypothetical scenarios.
Number of subjects: 282
Study 27466073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentist agreement with the efficacy of assessment for caries risk.
Number of subjects: 282
Study 27466607 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum zonulin group (<46.4 ng/mL)
Number of subjects: 100
Study 27467111 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) monitoring of abdominal oxygenation (ArSO2) at first enteral feed
Number of subjects: 61
Study 27467111 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic-cerebral oxygenation ratio calculation
Number of subjects: 61
Study 27467121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 400 mg q.d.
Number of subjects: 45
Study 27467121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 600 mg q.d.
Number of subjects: 45
Study 27467121 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib 800 mg q.d.
Number of subjects: 45
Study 27467683 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcrystalline zinc hydroxyapatite (mHA) dentifrice, n = 33
Number of subjects: 70
Study 27467683 — intervention group
Group type: COMPARATOR
Intervention: AmF/SnF2 dentifrice, n = 34
Number of subjects: 70
Study 27467683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mHA and AmF/SnF2 dentifrices
Number of subjects: 70
Study 27467907 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1782
Study 27467907 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score for atrial fibrillation occurrence
Number of subjects: 1782
Study 27468653 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile ACT intervention (8-week duration)
Number of subjects: 74
Study 27468937 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine testing for EGFR mutations
Number of subjects: 63
Study 27468937 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma testing for EGFR mutations
Number of subjects: 63
Study 27468937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined urine and plasma testing
Number of subjects: 63
Study 27468937 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring urine T790M levels in patients receiving rociletinib
Number of subjects: 63
Study 27468938 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA from plasma for EGFR mutation testing
Number of subjects: 1288
Study 27468938 — intervention group
Group type: COMPARATOR
Intervention: Tissue/cytologic samples for EGFR mutation testing
Number of subjects: 1288
Study 27470087 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporine A (CyA) 2 mg/kg body weight per day for 16 weeks
Number of subjects: 30
Study 27470600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 130
Study 27470602 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal remission karyotypes
Number of subjects: 258
Study 27470602 — intervention group
Group type: COMPARATOR
Intervention: Normal remission karyotypes
Number of subjects: 258
Study 27470602 — intervention group
Group type: EXPERIMENTAL
Intervention: Any clonal or non-clonal chromosome abnormality at complete remission
Number of subjects: 258
Study 27470602 — intervention group
Group type: COMPARATOR
Intervention: Exclusively normal metaphases
Number of subjects: 258
Study 27471042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SES families (census tracts with ≥15% living in poverty)
Number of subjects: 61
Study 27471042 — intervention group
Group type: COMPARATOR
Intervention: High SES families (census tracts with <15% living in poverty)
Number of subjects: 61
Study 27471224 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR identified individuals in need of CRC screening (520 individuals)
Number of subjects: 800
Study 27471224 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR flagged individuals as up-to-date in their screening (280 individuals)
Number of subjects: 800
Study 27471224 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients incorrectly classified as eligible (61 individuals)
Number of subjects: 800
Study 27471593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 10
Study 27471593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemonade (90 g/L carbohydrates)
Number of subjects: 10
Study 27471593 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline (9 g/L)
Number of subjects: 10
Study 27471619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Gram-positive antibiotics in CLL patients (n = 45/800)
Number of subjects: 922
Study 27471619 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Gram-positive antibiotics in relapsed lymphoma patients (n = 21/122)
Number of subjects: 922
Study 27472034 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 102
Study 27472034 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy with or without radiotherapy (C/R)
Number of subjects: 102
Study 27472156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy with baseline CD138 measurement
Number of subjects: 177
Study 27472156 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological prognostic score including CD138 and LDH values
Number of subjects: 177
Study 27473031 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa treatment
Number of subjects: 16
Study 27473040 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of violence from school staff
Number of subjects: 3565
Study 27473040 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of violence from other students
Number of subjects: 3565
Study 27473040 — intervention group
Group type: EXPERIMENTAL
Intervention: Low school connectedness
Number of subjects: 3565
Study 27473040 — intervention group
Group type: EXPERIMENTAL
Intervention: Never feeling close to other students at school
Number of subjects: 3565
Study 27473040 — intervention group
Group type: EXPERIMENTAL
Intervention: Attending an urban school
Number of subjects: 3565
Study 27473119 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic ICU admission (intervention group)
Number of subjects: 3036
Study 27473119 — intervention group
Group type: COMPARATOR
Intervention: Standard practices regarding ICU admission (control group)
Number of subjects: 3036
Study 27473350 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH infusion
Number of subjects: 28
Study 27473350 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injection
Number of subjects: 28
Study 27473473 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 27473569 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Education Intervention (DEI)
Number of subjects: 350
Study 27473569 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report depression screening tool (PHQ-9) via customized web application
Number of subjects: 350
Study 27473726 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction or total elimination of animal protein from the diet
Number of subjects: 0
Study 27473726 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological therapies
Number of subjects: 0
Study 27473726 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 0
Study 27473726 — intervention group
Group type: EXPERIMENTAL
Intervention: Online study platform
Number of subjects: 0
Study 27473815 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide and capecitabine-based preoperative chemoradiation therapy (CRT)
Number of subjects: 22
Study 27473949 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR bacteria
Number of subjects: 1000
Study 27473949 — intervention group
Group type: COMPARATOR
Intervention: Other pathogens
Number of subjects: 1000
Study 27474016 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear growth (measured by length-for-age z score)
Number of subjects: 3700
Study 27474016 — intervention group
Group type: COMPARATOR
Intervention: Developmental stimulation or maternal supplementation
Number of subjects: 3700
Study 27474016 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth faltering
Number of subjects: 3700
Study 27474021 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D (full factorial randomization)
Number of subjects: 2573
Study 27474021 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium with vitamin D (two-group randomization)
Number of subjects: 2573
Study 27474021 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alone (two-group randomization)
Number of subjects: 2573
Study 27474021 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during 3-month single-blinded run-in)
Number of subjects: 2573
Study 27474385 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 2 (moderate risk)
Number of subjects: 624
Study 27474385 — intervention group
Group type: EXPERIMENTAL
Intervention: Profile 3 (high risk)
Number of subjects: 624
Study 27474385 — intervention group
Group type: COMPARATOR
Intervention: Profile 1 (low risk)
Number of subjects: 624
Study 27474763 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg every 4 weeks for 4 months
Number of subjects: 20
Study 27475428 — intervention group
Group type: EXPERIMENTAL
Intervention: TPCS2a (0.25 mg/kg, escalated to 0.5, 1.0, and 1.5 mg/kg) followed by bleomycin (15,000 IU/m²) and laser illumination (652 nm, 60 J/cm²)
Number of subjects: 22
Study 27475428 — intervention group
Group type: EXPERIMENTAL
Intervention: TPCS2a (1.0 mg/kg)
Number of subjects: 22
Study 27475428 — intervention group
Group type: EXPERIMENTAL
Intervention: TPCS2a (1.5 mg/kg)
Number of subjects: 22
Study 27475428 — intervention group
Group type: EXPERIMENTAL
Intervention: TPCS2a (0.25 mg/kg)
Number of subjects: 22
Study 27475428 — intervention group
Group type: EXPERIMENTAL
Intervention: TPCS2a (not specified)
Number of subjects: 22
Study 27475524 — intervention group
Group type: EXPERIMENTAL
Intervention: Low MIP (MIP ≤30 cmH2O)
Number of subjects: 124
Study 27475524 — intervention group
Group type: COMPARATOR
Intervention: High MIP (MIP >30 cmH2O)
Number of subjects: 124
Study 27475526 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact embryos with mitosis resumption after overnight culture
Number of subjects: 986
Study 27475526 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos with 8 cells after warming or >9 cells after overnight culture
Number of subjects: 986
Study 27475526 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos with <6 cells after warming or ≤6 cells after overnight culture
Number of subjects: 986
Study 27475526 — intervention group
Group type: COMPARATOR
Intervention: Embryos with fragmentation >10% and/or symmetry <75%
Number of subjects: 986
Study 27475674 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) dose of 36 Gy with a 9-Gy simultaneous in-field boost (SIB) to the positive margins (PM), delivered in 3 fractions.
Number of subjects: 13
Study 27475674 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) dose escalation plan up to 45 Gy.
Number of subjects: 13
Study 27475998 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level pregnancy test (MLPT)
Number of subjects: 404
Study 27476767 — intervention group
Group type: EXPERIMENTAL
Intervention: DHCE-MRI using Gd-EOB-DTPA
Number of subjects: 0
Study 27476767 — intervention group
Group type: COMPARATOR
Intervention: Post-treatment ICG retention test (ICG R)
Number of subjects: 0
Study 27476790 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT-ASCT with rituximab 375 mg/m(2), carmustine 400 mg/m(2), thiotepa 2×5 mg/kg, and stem cell infusion
Number of subjects: 79
Study 27476790 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment with five courses of intravenous rituximab 375 mg/m(2) and four courses of intravenous high-dose methotrexate 8000 mg/m(2)
Number of subjects: 79
Study 27476790 — intervention group
Group type: EXPERIMENTAL
Intervention: HCT-ASCT
Number of subjects: 79
Study 27476790 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 79
Study 27476810 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4.5 g 2-3 times daily by intermittent infusion
Number of subjects: 60
Study 27476810 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin trough level of 22.5 mg/L
Number of subjects: 60
Study 27476810 — intervention group
Group type: EXPERIMENTAL
Intervention: Total piperacillin trough levels threshold of 70 mg/L
Number of subjects: 60
Study 27476810 — intervention group
Group type: EXPERIMENTAL
Intervention: Total piperacillin target range ≥70 mg/L
Number of subjects: 60
Study 27477483 — intervention group
Group type: EXPERIMENTAL
Intervention: GG genotype for SNP rs1800629 at the TNFA gene
Number of subjects: 840
Study 27477483 — intervention group
Group type: COMPARATOR
Intervention: A-allele subjects
Number of subjects: 840
Study 27477483 — intervention group
Group type: EXPERIMENTAL
Intervention: GG subjects for SNP rs1800629
Number of subjects: 840
Study 27478115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month triple antithrombotic therapy (TAT)
Number of subjects: 568
Study 27478115 — intervention group
Group type: COMPARATOR
Intervention: >1-month triple antithrombotic therapy (TAT)
Number of subjects: 568
Study 27478115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month TAT
Number of subjects: 568
Study 27478115 — intervention group
Group type: COMPARATOR
Intervention: >1-month TAT
Number of subjects: 568
Study 27478897 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with colic
Number of subjects: 28
Study 27478897 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 28
Study 27479107 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 178
Study 27479177 — intervention group
Group type: EXPERIMENTAL
Intervention: NS-018 (300 mg once daily)
Number of subjects: 48
Study 27479781 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 850000
Study 27479781 — intervention group
Group type: COMPARATOR
Intervention: Other phosphate binders (concomitant therapy)
Number of subjects: 850000
Study 27479781 — intervention group
Group type: COMPARATOR
Intervention: Historical control (before availability of lanthanum carbonate)
Number of subjects: 850000
Study 27479814 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution imaging (optical coherence tomography [OCT] and adaptive optics scanning light ophthalmoscopy [AOSLO])
Number of subjects: 51
Study 27479814 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak cone density measurement
Number of subjects: 51
Study 27479814 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of foveal outer nuclear layer thickness using OCT
Number of subjects: 51
Study 27479825 — intervention group
Group type: EXPERIMENTAL
Intervention: International Myeloma Working Group score
Number of subjects: 125
Study 27479825 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index
Number of subjects: 125
Study 27479825 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised Myeloma Comorbidity Index
Number of subjects: 125
Study 27479825 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation-Comorbidity Index
Number of subjects: 125
Study 27479825 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Feinstein Index
Number of subjects: 125
Study 27480288 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic-controlled capsule endoscopy (MCCE)
Number of subjects: 52
Study 27480830 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salicylate avoidance
Number of subjects: 0
Study 27480830 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene-modifying drugs
Number of subjects: 0
Study 27480830 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization with daily aspirin therapy
Number of subjects: 0
Study 27480854 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily therapy with 250 mg of AZM (n = 77)
Number of subjects: 221
Study 27480854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy with 500 mg of AZM three times weekly (n = 89)
Number of subjects: 221
Study 27480854 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily therapy with 250 mg of AZM for MABC-LD (n = 55)
Number of subjects: 221
Study 27480993 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 120
Study 27480993 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 120
Study 27481622 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte surface markers (biomarkers) assessed using flow cytometry in patients with suspected sepsis (n=300)
Number of subjects: 500
Study 27481622 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte surface markers (biomarkers) assessed using flow cytometry in critically ill patients with established sepsis (n=100)
Number of subjects: 500
Study 27481622 — intervention group
Group type: COMPARATOR
Intervention: Leucocyte surface markers (biomarkers) assessed using flow cytometry in age and gender matched patients without suspicion of infection (n=100)
Number of subjects: 500
Study 27482854 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization 5-Item Well-Being Index (WHO-5)
Number of subjects: 262
Study 27482854 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire (PHQ-9)
Number of subjects: 262
Study 27482854 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory II (BDI-II)
Number of subjects: 262
Study 27482854 — intervention group
Group type: COMPARATOR
Intervention: Montgomery-Åsberg Depression Rating Scale (MADRS)
Number of subjects: 262